Pharmaceutical Combination and Use Thereof
US-2022142975-A1 · May 12, 2022 · US
Methods for cancer therapy
US12544370B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12544370-B2 |
| Application number | US-202318473796-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 25, 2023 |
| Priority date | Dec 3, 2018 |
| Publication date | Feb 10, 2026 |
| Grant date | Feb 10, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
First claim
Opening claim text (preview).
We claim: 1 . A method for treating cancer in a patient, comprising orally administering to the patient once every other day (QOD) a therapeutically effective amount of a compound of formula (I-A): or a pharmaceutically acceptable salt thereof, wherein the cancer is chronic myeloid leukemia caused by BCR-ABL mutation that is resistant to ponatinib, wherein the BCR-ABL mutation is T315I. 2 . The method of claim 1 , wherein the BCR-ABL mutation is BCR-ABL E255V/T315I or BCR-ABL Y253H/T315I . 3 . The method of claim 1 , wherein the therapeutically effective amount is from about 1 mg to about 100 mg. 4 . The method of claim 1 , wherein the therapeutically effective amount is from about 1 mg to about 80 mg. 5 . The method of claim 1 , wherein the therapeutically effective amount is from about 1 mg to about 60 mg. 6 . The method of claim 1 , wherein the therapeutically effective amount is about 1 mg, about 2 mg, about 4 mg, about 8 mg, about 12 mg, about 20 mg, about 30 mg, about 40 mg, about 45 mg, about 50 mg, or about 60 mg. 7 . The method of claim 1 , wherein the compound of formula (I-A) or a pharmaceutically acceptable salt thereof, is formulated in a solid dosage form. 8 . The method of claim 6 , wherein the compound of formula (I-A), or pharmaceutically acceptable salt thereof is administered once every other day (QOD) during a 28-day treatment cycle. 9 . The method of claim 1 , wherein the chronic myeloid leukemia is relapsed chronic myeloid leukemia. 10 . The method of claim 1 , wherein the chronic myeloid leukemia is refractory chronic myeloid leukemia.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
specific for leukemia · CPC title
- A61K31/496Primary
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
- A61K31/437Primary
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12544370B2 cover?
- The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
- Who is the assignee on this patent?
- Ascentage Pharma Suzhou Co Ltd, Ascentage Pharma Group Corp Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/496. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).